Eduard Serra

Eduard Serra

Auto-generated profile, based on publicly available information

Eduard Serra

Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, 08916 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Bioinformatics
Verified
Journal Article
Open access
PDF file
BGBernat Gel
Bernat Gel
ADAnna Díez-Villanueva
Anna Díez-Villanueva
ESEduard Serra
Eduard Serra
MBMarcus Buschbeck
Marcus Buschbeck
MPMiguel A. Peinado
Miguel A. Peinado
RMRoberto Malinverni
Roberto Malinverni
Motivation: Statistically assessing the relation between a set of genomic regions and other genomic features is a common challenging task in genomic and epigenomic analyses. Randomization based approaches implicitly take into account the complexity of the genome without the need of assuming an underlying statistical model. Summary: regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association. Availability and implementation: regioneR is an R package released under Artistic-2.0 License. The source code and documents are freely available through Bioconductor ( http://www.bioconductor.org/packages/regioneR ). Contact:rmalinverni@carrerasresearch.org

18 September 2005 in Nature
Verified
Journal Article
Closed access
PDF file
ACAlejandro Colman-Lerner
Alejandro Colman-Lerner
AGAndrew Gordon
Andrew Gordon
ESEduard Serra
Eduard Serra
TCTina Chin
Tina Chin
OROrna Resnekov
Orna Resnekov
RBRoger Brent
Roger Brent

22 January 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EAElisabet Ars
Elisabet Ars
ESEduard Serra
Eduard Serra
JGJudit García
Judit García
HKHelena Kruyer
Helena Kruyer
AGAntonia Gaona
Antonia Gaona
XEXavier Estivill
Xavier Estivill
Neurofibromatosis type 1 (NF1) is one of the most common inherited disorders in humans and is caused by mutations in the NF1 gene. To date, the majority of the reported NF1 mutations are predicted to result in protein truncation, but very few studies have correlated the causative NF1 mutation with its effect at the mRNA level. We have applied a whole NF1 cDNA screening methodology to the study of 80 unrelated NF1 patients and have identified 44 different mutations, 32 being novel, in 52 of these patients. Mutations were detected in 87% of the familial cases, but in 51% of the sporadic ones. At least 15 of the 80 NF1 patients (19%) had recurrent mutations. The study shows that in 50% of the patients in whom the mutations were identified, these resulted in splicing alterations. Most of the splicing mutations did not involve the conserved AG/GT dinucleotides of the splice sites. One frameshift, two nonsense and two missense mutations were also responsible for alterations in mRNA splicing. The location and type of mutation within the NF1 gene, and its putative effect at the protein level, do not indicate any relationship to any specific clinical feature of NF1. The high proportion of aberrant spliced transcripts detected in NF1 patients stresses the importance of studying mutations at both the genomic and RNA level. It is possible that part of the clinical variability in NF1 could be due to mutations affecting mRNA splicing, which is the most common molecular defect in NF1.

11 December 2008 in Nature
Verified
Journal Article
Open access
PDF file
RYRichard C. Yu
Richard C. Yu
CPC. Gustavo Pesce
C. Gustavo Pesce
ACAlejandro Colman-Lerner
Alejandro Colman-Lerner
LLLarry Lok
Larry Lok
DPDavid Pincus
David Pincus
RBRoger Brent
Roger Brent
Haploid Saccharomyces cerevisiae yeast cells use a prototypic cell signalling system to transmit information about the extracellular concentration of mating pheromone secreted by potential mating partners. The ability of cells to respond distinguishably to different pheromone concentrations depends on how much information about pheromone concentration the system can transmit. Here we show that the mitogen-activated protein kinase Fus3 mediates fast-acting negative feedback that adjusts the dose response of the downstream system response to match the dose response of receptor-ligand binding. This ‘dose–response alignment’, defined by a linear relationship between receptor occupancy and downstream response, can improve the fidelity of information transmission by making downstream responses corresponding to different receptor occupancies more distinguishable and reducing amplification of stochastic noise during signal transmission. We also show that one target of the feedback is a previously uncharacterized signal-promoting function of the regulator of G-protein signalling protein Sst2. Our work suggests that negative feedback is a general mechanism used in signalling systems to align dose responses and thereby increase the fidelity of information transmission.

1 December 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ESEduard Serra
Eduard Serra
TRThorsten Rosenbaum
Thorsten Rosenbaum
UWUrsula Winner
Ursula Winner
RARosa Aledo
Rosa Aledo
EAElisabet Ars
Elisabet Ars
Conxi LázaroConxi Lázaro
Conxi Lázaro
Neurofibromas are one of the most characteristic features of neurofibromatosis type 1 (NF1), an inherited autosomal-dominant neurogenetic disorder affecting 1 in 3500 individuals worldwide. These benign tumors mainly consist of Schwann cells (SCs) and fibroblasts. Recent evidence demonstrates that somatic mutations at the NF1 gene are found in neurofibromas, but it has not been demonstrated whether SCs, fibroblasts and/or both cell types bear a somatic loss of NF1. We recently established a cell culture system that allows selective expansion of human SCs from neurofibromas. We cultured pure populations of SCs and fibroblasts derived from 10 neurofibromas with characterized NF1 mutations and found that SCs but not fibroblasts harbored a somatic mutation at the NF1 locus in all studied tumors. Furthermore, by culturing neurofibroma-derived SCs under different in vitro conditions we were able to obtain two genetically distinct SC subpopulations: NF1–/– and NF1+/–. These data strongly support the idea that NF1 mutations in SCs, but not in fibroblasts, correlate to neurofibroma formation and demonstrate that only a portion of SCs in neurofibromas have mutations in both NF1 alleles.

1 September 1997 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ESEduard Serra
Eduard Serra
SPSusana Puig
Susana Puig
DODavid Otero
David Otero
AGAntonia Gaona
Antonia Gaona
HKHelena Kruyer
Helena Kruyer
Conxi LázaroConxi Lázaro
Conxi Lázaro